[Form 4] Bio-Rad Laboratories, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Colleen Corey, EVP Global Human Resources at Bio-Rad Laboratories (BIO), reported stock award vesting and a small sale. On 09/05/2025 Ms. Corey received 2,740 restricted stock units (each convertible to one share) that vest over four years at 25% per year. On 09/06/2025 she acquired an additional 576 shares on vesting and sold 209 shares at $295.43 per share. Following these transactions she beneficially owned 19,759 shares of Bio-Rad Class A common stock (direct) for non-derivative holdings and 2,740 RSUs shown as derivative holdings.

Positive

• Transparent disclosure of vesting schedule and transaction details
• Sale size is small relative to reported beneficial ownership (209 shares vs. 19,759 shares)

Negative

• None.

Insights

Financial Analyst

TL;DR: Routine executive compensation vesting with a minor disposition; does not materially change ownership or signal a major shift.

The Form 4 discloses standard equity compensation activity: a grant/vesting event and a small sale. The vesting of 2,740 RSUs increases potential future dilution modestly but is typical for executive remuneration. The 209-share sale at $295.43 generated proceeds but represents a very small fraction of the reported ~19,700 shares owned, so it is unlikely to alter market perception or control. No additional transactions, loans, or derivative exercises beyond vesting are reported.

Corporate Governance Expert

TL;DR: Disclosure is complete for the reported events; vesting schedule and sale are properly documented.

The filing includes relevant identifiers: reporting person, relationship (EVP, Global Human Resources), transaction codes (M and F), quantities, prices, and post-transaction holdings. The RSU vesting schedule is stated (25% per year over four years), meeting standard disclosure practices. There are no indications of Rule 10b5-1 plans or other arrangements disclosed on the form.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

COREY COLLEEN

(Last) (First) (Middle)

C/O BIO-RAD LABORATORIES, INC.

1000 ALFRED NOBEL DRIVE

(Street)

HERCULES CA 94547

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIO-RAD LABORATORIES, INC. [ BIO BIO.B ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Global Human Resources

3. Date of Earliest Transaction (Month/Day/Year)
09/05/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Bio-Rad A Common Stock	09/06/2025		M		576(1)	A	$0	19,759	D
Bio-Rad A Common Stock	09/06/2025		F		209	D	$295.43	19,550	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0(2)	09/05/2025		A		2,740		(3)	(3)	Bio-Rad A Common Stock	2,740	$0	2,740	D
Restricted Stock Units	$0(2)	09/06/2025		M			576	(3)	(3)	Bio-Rad A Common Stock	576	$0	1,728	D

Explanation of Responses:

1. Shares of Class A common stock acquired on the vesting of restricted stock units.

2. Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.

3. The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant.

Remarks:

	/s/ Colleen Corey	09/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did Colleen Corey report for BIO on the Form 4?

Ms. Corey reported the vesting of 2,740 RSUs on 09/05/2025, the vesting/acquisition of 576 shares on 09/06/2025, and a sale of 209 shares at $295.43 on 09/06/2025.

How many Bio-Rad (BIO) shares does Colleen Corey beneficially own after these transactions?

The Form 4 reports Ms. Corey beneficially owned 19,759 shares of Bio-Rad Class A common stock following the reported non-derivative transactions.

What is the vesting schedule for the restricted stock units reported?

Each RSU represents one share and the restricted stock units vest over four years at 25% per year on the yearly anniversary of the grant.

Was a 10b5-1 trading plan or other plan referenced in this filing?

No 10b5-1 plan or similar trading-plan indication is disclosed in the provided Form 4 content.

What do transaction codes M and F mean in this filing?

The Form uses codes M (acquisition on vesting/execution per the filer) and F (disposition by a sale), as shown in the transaction rows; the filing provides quantities and price for the F-coded sale.